Lipoprotein(a) Reduction in Persons with Cardiovascular Disease

Sotirios Tsimikas; Ewa Karwatowska‐Prokopczuk; Ioanna Gouni‐Berthold; Jean‐Claude Tardif; Seth J. Baum; Elizabeth Steinhagen-Thiessen; Michael D. Shapiro; Erik S.G. Stroes; Patrick M. Moriarty; Børge G. Nordestgaard; Shuting Xia; Jonathan Guerriero; Nicholas J. Viney; Louis O’Dea; Joseph L. Witztum

doi:10.1056/nejmoa1905239

January 1, 2020New England Journal of MedicineOpen Access

Lipoprotein(a) Reduction in Persons with Cardiovascular Disease

View Full Paper

Ask AI

Bookmark

Share

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

APO(a)-LRx reduced lipoprotein(a) levels in a dose-dependent manner in patients who had elevated lipoprotein(a) levels and established cardiovascular disease. (Funded by Akcea Therapeutics; ClinicalTrials.gov number, NCT03070782.).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Tsimikas et al. (2020) studied this question.

synapsesocial.com/papers/69ab442a91ed9fe11743f389 https://doi.org/10.1056/nejmoa1905239

View Full Paper

Ask AI

Bookmark

Share

Lipoprotein(a) Reduction in Persons with Cardiovascular Disease

Ask about this paper

Abstract

Discussion

Cite This Study

Lipoprotein(a) Reduction in Persons with Cardiovascular Disease

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading